Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Summary

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.

Timeline

Start

2021-03-03

Primary completion

2025-05-12

Completion

2025-11-09

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual”

Drugs

Indications